Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
A comprehensive understanding of subtypes of HR+/HER2- breast cancer facilitates development of a multipronged precision medicine approach that can be translated from bench to bedside.
Authors
- Zhi‐Ming Shao (ORCID: https://orcid.org/0000-0002-4503-148X)
- Tong Fu (ORCID: https://orcid.org/0000-0002-1569-5111)
- Yi‐Zhou Jiang (ORCID: https://orcid.org/0000-0003-3699-2630)
- Hu-Yun-Long Zhang (ORCID: https://orcid.org/0009-0009-5380-3062)
- Xi Jin (ORCID: https://orcid.org/0000-0003-2624-1323)
- Yi-Fan Xie
- Xiaohua Zeng (ORCID: https://orcid.org/0000-0001-5810-8055)
- Yi-Fan Zhou (ORCID: https://orcid.org/0000-0003-3134-0174)
- Yi-Yu Chen (ORCID: https://orcid.org/0009-0006-5933-0612)
- Xiu-Zhi Zhu (ORCID: https://orcid.org/0000-0001-5564-1719)
- Ming-Liang Jin
- Ya-Xin Zhao
Institutions
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1158/0008-5472.can-24-5002
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81